Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Impact · against what's priced in

Evaxion's release of three-year durability data and high target precision for EVX-01 provides a concrete valuation floor for the asset. The sustained clinical responses in advanced melanoma patients shift the risk profile from short-term efficacy to long-term survival potential, increasing the likelihood of Phase 3 success and M&A interest.

EVAX+0.60: No priced-in read yet

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

What matters in this story

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

What matters in this story

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option

How each ticker is affected

Track these names every morning.

Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports

Summit Expands Ivonescimab Development Into Biliary Tract Cancer

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

What matters in this story

Next reads from the same story arc

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

What matters in this story

Next reads from the same story arc

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option

How each ticker is affected

Track these names every morning.

Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports

Summit Expands Ivonescimab Development Into Biliary Tract Cancer

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path